Baxter Stock Plummets 15% After Mixed Q3 Earnings – What Investors Should Know
Baxter shares fell about 16% to $19 on Oct. 30 after cutting its 2025 outlook and missing Q3 sales forecasts. Q3 revenue rose 5% to $2.84 billion, but sales missed estimates; adjusted EPS of $0.69 beat expectations. The company halted Novum IQ infusion pump shipments after two patient deaths and reported hurricane-related supply disruptions. Andrew Hider became CEO in July.
